Compounded Topical Composition Using Ground Antiviral Powders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional transdermal creams for topical administration have limitations such as addressing limited medical conditions, causing adverse side effects, and having limited shelf lives, along with inefficient manufacturing processes that lack precision in active ingredient delivery.
Innovation Solution
A compounded topical composition is developed, incorporating active components like antiviral agents (e.g., acyclovir), local anesthetics (e.g., lidocaine and prilocaine), and additional agents in precise amounts, combined with a topical base component, using fine powders generated from ground oral tablets to ensure precise dosing and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional transdermal creams are used, then they can deliver medication to the skin, but they have limited shelf lives and cause adverse side effects
Solution Approach 1:
The patent changes the formulation parameters by using a compounded composition with specific ratios of antiviral agents (acyclovir, penciclovir, famciclovir) and local anesthetics (lidocaine, prilocaine) in a cream base. This customized parameter configuration optimizes both shelf life and reduces adverse effects by controlling the concentration and interaction of active ingredients.
Solution Approach 2:
The invention creates a composite topical composition combining multiple active ingredients (antivirals and local anesthetics) with a cream base matrix. This composite formulation improves stability and extends shelf life while the synergistic combination of ingredients enhances therapeutic efficacy and reduces adverse effects compared to single-agent conventional creams.
2Adaptability or versatility
If conventional transdermal creams are used, then they can treat certain medical conditions, but they address limited medical conditions and have limited versatility
Solution Approach 1:
The compounded topical composition achieves multi-functionality by incorporating both antiviral agents (acyclovir, penciclovir, famciclovir) and local anesthetics (lidocaine, prilocaine) in a single formulation. This universal cream can treat multiple conditions including viral infections (herpes simplex, varicella zoster) and provide pain relief, replacing the need for multiple separate conventional creams.
Solution Approach 2:
The patent employs dynamic formulation design where the cream base can be adjusted to accommodate different concentrations and combinations of active ingredients. This dynamic adaptability allows the same basic formulation framework to treat various medical conditions by simply changing the ingredient ratios, without requiring entirely different product development.
3Manufacturing precision
If conventional manufacturing methods are used, then transdermal creams can be produced, but the manufacturing process is inefficient and lacks precision in active ingredient delivery
Solution Approach 1:
The patent implements preliminary action by pre-calculating and pre-measuring precise amounts of active ingredients during the formulation design stage. The compounded composition specifies exact concentrations of antivirals and local anesthetics before manufacturing, allowing for precise dosing to be built into the production process itself rather than adjusted during or after manufacturing.
Solution Approach 2:
The invention replaces complex multi-step mechanical manufacturing processes with a simplified compounded formulation approach. By using a standardized cream base and pre-determined ingredient ratios, the manufacturing process is reduced to mixing and homogenizing components, significantly improving both precision of active ingredient delivery and manufacturing efficiency.
Data Source
AI summary
A compounded topical composition may include an antiviral component, a topical base component, and a local anesthetic component. The antiviral component may include fine powder obtained by grinding oral tablets of one or more antiviral actives. The topical component may include the local anesthetic component. The local anesthetic component may be present in an amount between about 2% and about 8% by weight of the compounded topical composition and the antiviral component may be present in an amount between 4% and 12% by weight of the compounded topical composition. The antiviral component may include acyclovir, valaciclovir, penciclovir, famciclovir, or combinations thereof, and the topical base component may be a lidocaine topical, a lidocaine and prilocaine topical, or both.